• LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands

Please reload

Recent Posts

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

May 12, 2017

1/2
Please reload

Featured Posts

SynGEM publication paper of the month on ReSViNET

April 5, 2019

#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as paper of the month March. The study which was executed by Imperial College London, showed that #SynGEM is safe and capable of inducing long term immune responses. A commentary published in the same journal suggested to test the vaccine in a human challenge study. The author manuscript can now be downloaded free of charge from the ReSViNET website

Please reload

Follow Us
Search By Tags